Author

S. Schaller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

H. Strandt· 2 shared J. Horejs-Hoeck· 2 shared R. Bauer· 2 shared S. Winkler· 2 shared T. Neuper· 2 shared A. Paini· 1 shared C. Blöchl· 1 shared C. G. Huber· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

H. Strandt

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Systematic Evaluation of High-Throughput PBK Modelling Strategies for the Prediction of Intravenous and Oral Pharmacokinetics in Humans

R. Geci, D. Gadaleta, M. Garcia de Lomana, R. Ortega-Vallbona, E. Colombo, E. Serrano-Candelas, A. Paini, L. Kuepfer, S. Schaller

This study evaluates high-throughput PBK modelling strategies for predicting human intravenous and oral pharmacokinetics using in vitro and in silico data.

bioRxiv · Mar 20, 2024Pharmacology & Toxicology

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia

M. Luciano, C. Blöchl, J. Vetter, L. Urwanisch, T. Neuper, D. P. Elmer, R. Bauer, H.-H. Dang, H. Strandt, D. Neureiter, P. Krenn, S. Tesanovic, S. Rieser, O. Bergsleitner, L. Zell, , J. Horejs-Hoeck

This study shows that inhibiting the NLRP3 inflammasome reduces AML cell proliferation by promoting eIF2 phosphorylation and cell cycle arrest.

bioRxiv · Jun 25, 2021 · PreprintImmunology

Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma

E. Korotchenko, V. Schiessl, S. Scheiblhofer, I. Joubert, H. Strandt, T. Neuper, M. Sarajlic, R. Bauer, M. Geppert, D. Joedicke, S. Wildner, S. Schaller, S. Winkler, G. Gadermaier, J. Horejs-Hoeck, R. Weiss

This study shows that LamOVA, a hypoallergenic beta-glucan neoglycoconjugate, suppresses lung inflammation and reduces side effects in a mouse asthma model when delivered via laser-facilitated epicutaneous immunotherapy.

bioRxiv · Jan 18, 2020Immunology

Ephrin receptor A4 (EphA4) is a new Kaposi’s sarcoma-associated herpesvirus virus entry receptor

J. Chen, Z. Zhang, S. Schaller, T. S. Jardetzky, R. Longnecker

This study identifies EphA4 as a new Kaposi’s sarcoma-associated herpesvirus entry receptor, showing it promotes viral fusion and infection better than EphA2 in HEK293T cells.

bioRxiv · Jan 3, 2019Microbiology